Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report

IF 3 Q2 ONCOLOGY

JTO Clinical and Research Reports Pub Date : 2024-02-28 DOI:10.1016/j.jtocrr.2024.100657

Masahiro Torasawa MD , Tatsuya Yoshida MD, PhD , Kouya Shiraishi PhD , Naoko Goto BS , Toshihide Ueno PhD , Hitoshi Ichikawa MD, PhD , Shigehiro Yagishita MD, PhD , Shinji Kohsaka MD, PhD , Yasushi Goto MD, PhD , Yasushi Yatabe MD, PhD , Akinobu Hamada PhD , Hiroyuki Mano MD, PhD , Yuichiro Ohe MD, PhD

{"title":"Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report","authors":"Masahiro Torasawa MD , Tatsuya Yoshida MD, PhD , Kouya Shiraishi PhD , Naoko Goto BS , Toshihide Ueno PhD , Hitoshi Ichikawa MD, PhD , Shigehiro Yagishita MD, PhD , Shinji Kohsaka MD, PhD , Yasushi Goto MD, PhD , Yasushi Yatabe MD, PhD , Akinobu Hamada PhD , Hiroyuki Mano MD, PhD , Yuichiro Ohe MD, PhD","doi":"10.1016/j.jtocrr.2024.100657","DOIUrl":null,"url":null,"abstract":"<div><p>Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC). Here, we present the case of a patient with metastatic TC harboring a <em>KIT</em> exon 11 deletion and amplification. The patient exhibited a remarkable response to lenvatinib but experienced rapid disease progression after discontinuation of lenvatinib, referred to as a “disease flare.” This case report indicates that <em>KIT</em> mutations and amplification can predict lenvatinib response in patients with TC. However, in such cases, there might be a risk of disease flares after lenvatinib discontinuation.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 4","pages":"Article 100657"},"PeriodicalIF":3.0000,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000274/pdfft?md5=b9ec22f6643d5497789d13c673ed5b47&pid=1-s2.0-S2666364324000274-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364324000274","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC). Here, we present the case of a patient with metastatic TC harboring a KIT exon 11 deletion and amplification. The patient exhibited a remarkable response to lenvatinib but experienced rapid disease progression after discontinuation of lenvatinib, referred to as a “disease flare.” This case report indicates that KIT mutations and amplification can predict lenvatinib response in patients with TC. However, in such cases, there might be a risk of disease flares after lenvatinib discontinuation.

查看原文本刊更多论文

一名携带 KIT 外显子 11 突变的胸腺癌患者对伦伐替尼的快速反应和停药后的疾病复发：病例报告

伦伐替尼是一种针对c-Kit和其他激酶的多靶点酪氨酸激酶抑制剂，在治疗晚期或转移性胸腺癌（TC）方面具有良好的疗效。在此，我们介绍一例携带 KIT 第 11 号外显子缺失和扩增的转移性胸腺癌患者。该患者对来伐替尼有明显反应，但停用来伐替尼后疾病迅速进展，被称为 "疾病爆发"。该病例报告表明，KIT突变和扩增可预测来伐替尼对TC患者的反应。然而，在这种情况下，停用来伐替尼后可能会出现疾病复发的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JTO Clinical and Research Reports Medicine-Oncology

CiteScore

4.20

自引率

0.00%

发文量

145

审稿时长

19 weeks